Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to Onc201 Treatment of H3 K27m-Mutant Diffuse Midline Gliomas Published in Cancer Discovery
August 16, 2023 at 10:05 am EDT
Share
Chimerix announced the publication of data in support of the Company's first-in-class small molecule impipridone, ONC201, as a treatment for H3 K27M-mutant diffuse midline gliomas (H3K27M-DMG) in the peer-reviewed journal, Cancer Discovery, a journal of the American Association for Cancer Research. The manuscript titled, "Clinical efficacy of ONC201 in H3K27M-mutant diffuse Midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways," reports survival analyses of 71 patients with H3 K27M-DMG treated with ONC201 which demonstrated promising results in a patient population with a poor prognosis and few treatment options. In addition to assessing clinical outcomes, the study corroborated mechanistic findings from laboratory models in samples from treated patients that demonstrated the ability of ONC201 to disrupt metabolic pathways and reverse the epigenetic consequence (H3K27me3-loss) of the H3 K27M mutation.
Chimerix, Inc. is a biotechnology company. The Company is focused on developing medicines that address unmet medical needs. The Company's product Imipridones is a cancer therapy that provides ONC201, which is in clinical-stage development for H3 K27M-mutant glioma as its lead indication. In addition, imipridone ONC206 is in dose-escalating clinical trials. Imipridones target specific G protein-coupled receptors (GPCRs) and mitochondrial caseinolytic protease P (ClpP), resulting in cancer cell death. The Company's product Imipridone chemical scaffold provides an opportunity to target GPCRs and ClpP with tunable specificity and modality, which enables therapeutic use for cancer and other diseases. Its ONC206 is an imipridone, Dopamine Receptor D2 (DRD2) antagonist and ClpP agonist. Its ONC212 is an imipridone, an investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP. Its CMX521 is a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2.
Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to Onc201 Treatment of H3 K27m-Mutant Diffuse Midline Gliomas Published in Cancer Discovery
CHIMERIX, INC. 
